Pharmaceutical manufacturers regard common regulatory policies as key to facilitating access to foreign markets, to patients from other regions for clinical trials, and to lower cost suppliers and operational support, observed Peter Honig, vice-president global regulatory affairs at AstraZeneca. Honig noted the importance of standards in reducing the cost and time of drug development in a February workshop organized by the Institute of Medicine (IOM) Forum on Drug Discovery, Development and Translation (1). In recent years, IOM has examined clinical trial operations and development of medical countermeasures, new treatments for tuberculosis, and drug-diagnostic combinations. This gathering of regulatory authorities and industry leaders from around the world sought to take a fresh look at international regulatory issues in the face of uncertainty about the future of the ICH standards-setting process, concerns about the growing cost of new drug development, and alarm over the increase in substandard medical products in all regions.
In addition to highlighting problems created by divergent clinical research and data requirements, participants emphasized the need for common technical standards to ensure drug quality, reduce redundant manufacturing plant inspections, and help regulators detect substandard products and ensure the integrity of increasingly long supply chains. Individual countries differ in how they implement ICH quality standards, adding specifications and content to the common dossier format for submitting chemistry, manufacturing, and controls (CMC) information, reported Diane Zezza, vice-president and global head for regulatory CMC at Novartis, in summarizing concerns related to manufacturing standards and processes. And postapproval changes are even more divergent in terms of data requirements and timing of filings, a situation that can inhibit continuous improvement efforts.The group urged harmonization efforts to target differing import-testing requirements, which can lead to product recalls and shortages. A related goal is to reduce differences in how field inspectors apply and interpret GMPs and cite violations in inspection reports. Multiple pre-approval inspections by different regulatory authorities are a perennial burden on manufacturers. One encouraging sign is the willingness of more countries to accept inspection standards established by the Pharmaceutical Inspection Convention and Co-operation Scheme (PIC/S) and to voluntarily share redacted GMP information and inspection reports on active ingredients.